Northeast Alabama Family Foot Care, Pc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 627 E Main St, Suite B, Albertville, AL 35950 Phone: 256-894-5900 |
Dr. Philip M Traynor, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 9625 Us Highway 431, Albertville, AL 35950 Phone: 256-878-0971 |
Marshall Foot Clinic Podiatrist Medicare: Medicare Enrolled Practice Location: 3460 Us Highway 431 Ste B, Albertville, AL 35950 Phone: 256-840-4810 Fax: 256-840-4815 |
Robson F Araujo, DPM Podiatrist - Foot Surgery Medicare: Accepting Medicare Assignments Practice Location: 3460 Us Highway 431 Ste B, Albertville, AL 35950 Phone: 256-840-4810 Fax: 256-840-4815 |
Lakeview Family Foot Care L.l.c. Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 9625 Us Highway 431, Albertville, AL 35950 Phone: 256-660-1613 |
Northeast Alabama Family Footcare,l.l.c. Podiatrist - Foot Surgery Medicare: Not Enrolled in Medicare Practice Location: 627 E Main St, Suite B, Albertville, AL 35950 Phone: 256-894-5900 Fax: 256-894-5901 |
News Archive
Beyond the physical dangers of COVID-19, the pandemic has wreaked havoc mentally and emotionally. A new study suggests the pandemic may have had a greater impact on the mental health of women with a history of childhood abuse or intimate partner violence (IPV) than with women without such histories.
Chromosomal microarray analysis is able to identify significantly more clinically relevant information for prenatal diagnosis than is karyotyping, and is equally able to highlight aneuploidies and unbalanced rearrangements, US study findings suggest.
It's true that the brain governs the body, but the body also governs the brain, for example when the immune defense system makes us rest when we're sick. This is shown in research that the world's leading researchers and Nobel laureates will be presenting at an international conference in the research field of psychoneuroimmunology in Stockholm in June.
Arrowhead Research Corporation, a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic candidate targeting solid tumors. All patients participating in the trial have completed dosing with the exception of one patient who is still receiving treatment and will continue to be monitored.
Students of the Medicine Degree at the CEU UCH University in Castellón, Iván Echeverria and Carlos Galera-Román, and the student of the International Doctorate School of the CEU, Alejandro Fuertes-Saiz, have presented two pieces of research at the third edition of the International Congress of Dual Disorders, which was held in Madrid on June 19-22.
› Verified 4 days ago